Pyxis Oncology, Inc. (PYXS): Capital Expenditures
$9.0K
Year ended 2025-12-31
-88.8%
3-year compound annual growth
-64.0%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.0K | -96.2% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $237.0K | -96.5% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $6.73M | +5.1% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $6.40M | n/m | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $540.0K | -63.6% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $1.48M | n/a | 2022-03-29, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $9.0K | -96.2% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $109.0K | +505.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $0 | -100.0% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $51.3K | n/a |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $3.37M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | $235.0K | +167.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $1.0K | -91.7% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $67.0K | -91.2% |
| uniQure N.V. (QURE) | 2025-12-31 | $439.0K | -87.0% |
Compare PYXS, CVSI, ABUS, PTN side by side · Screen every company in Pharmaceutical Preparations ↗